Comment on: Thallas-Bonke et al. (2008) Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product–Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-α–Dependent Pathway: Diabetes 57:460–469, 2008
- From the Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine, Kurume, Japan
- Corresponding author: S. Yamagishi, MD, PHD, Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan. Email: shoichi{at}med.kurume-u.ac.jp
I read with interest the recent study by Thallas-Bonke et al. (1), which reported that inhibition of NADPH oxidase prevents advanced glycation end product (AGE)-mediated damage in diabetic nephropathy through a protein kinase C-α (PKC-α)-dependent pathway. As far as I know, this is the first study that clearly demonstrated the interaction of NADPH oxidase with PKC-α and AGEs in established diabetic nephropathy. In the schema of Fig. 7 of their article, the authors claimed that NADPH oxidase was a downstream molecule of the …
